LianBio ADR Performance
LIANDelisted Stock | USD 2.18 0.05 2.24% |
The company secures a Beta (Market Risk) of -0.61, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning LianBio ADR are expected to decrease at a much lower rate. During the bear market, LianBio ADR is likely to outperform the market. LianBio ADR right now secures a risk of 0.0%. Please verify LianBio ADR potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to decide if LianBio ADR will be following its current price movements.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days LianBio ADR has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, LianBio ADR is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
Begin Period Cash Flow | 98.9 M |
LianBio |
LianBio ADR Relative Risk vs. Return Landscape
If you would invest 218.00 in LianBio ADR on August 9, 2024 and sell it today you would earn a total of 0.00 from holding LianBio ADR or generate 0.0% return on investment over 90 days. LianBio ADR is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than LianBio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
LianBio ADR Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for LianBio ADR's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as LianBio ADR, and traders can use it to determine the average amount a LianBio ADR's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ||||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
LIAN |
Based on monthly moving average LianBio ADR is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of LianBio ADR by adding LianBio ADR to a well-diversified portfolio.
LianBio ADR Fundamentals Growth
LianBio Stock prices reflect investors' perceptions of the future prospects and financial health of LianBio ADR, and LianBio ADR fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on LianBio Stock performance.
Return On Equity | -0.32 | |||
Return On Asset | -0.22 | |||
Current Valuation | (182.65 M) | |||
Shares Outstanding | 108.06 M | |||
Price To Book | 0.15 X | |||
EBITDA | (105.26 M) | |||
Cash And Equivalents | 329.3 M | |||
Cash Per Share | 3.04 X | |||
Total Debt | 4.34 M | |||
Debt To Equity | 0.02 % | |||
Book Value Per Share | 1.89 X | |||
Cash Flow From Operations | (83.53 M) | |||
Earnings Per Share | (0.82) X | |||
Total Asset | 319.96 M | |||
Retained Earnings | (470.52 M) | |||
About LianBio ADR Performance
By examining LianBio ADR's fundamental ratios, stakeholders can obtain critical insights into LianBio ADR's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that LianBio ADR is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. Lianbio ADR operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 107 people.Things to note about LianBio ADR performance evaluation
Checking the ongoing alerts about LianBio ADR for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for LianBio ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.LianBio ADR is not yet fully synchronised with the market data | |
LianBio ADR has a very high chance of going through financial distress in the upcoming years | |
Net Loss for the year was (87.98 M) with profit before overhead, payroll, taxes, and interest of 0. | |
LianBio ADR currently holds about 329.3 M in cash with (83.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.04, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Over 79.0% of the company shares are owned by institutional investors |
- Analyzing LianBio ADR's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether LianBio ADR's stock is overvalued or undervalued compared to its peers.
- Examining LianBio ADR's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating LianBio ADR's management team can have a significant impact on its success or failure. Reviewing the track record and experience of LianBio ADR's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of LianBio ADR's stock. These opinions can provide insight into LianBio ADR's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in LianBio Stock
If you are still planning to invest in LianBio ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the LianBio ADR's history and understand the potential risks before investing.
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |